N/A
Completed N=5,044
Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19
Coronavirus Disease 2019 (COVID-19)
Source: ClinicalTrials.gov NCT04545047 ↗
Enrolled (actual)
5,044
Serious AEs
—
Results posted
Apr 2024
Primary outcomePrimary: All-cause Mortality — 40; 671 Person-trials
Summary
The purpose of this study is to assess whether convalescent plasma therapy is associated with reduced 30-day all-cause mortality in a population of Veteran inpatients with non-severe coronavirus disease 2019 (COVID-19).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY All-cause Mortality |
40; 671 | — |
Eligibility Criteria
Inclusion Criteria
- US Veterans aged 21-80 years old
- Hospitalized between May 1, 2020 and November 17, 2020 with a SARS-CoV-2 positive test, at a VA Medical Center where convalescent plasma had been administered to at least one patient and remained a current practice at that VA Medical Center
- SARS-CoV-2 positive test within 7 days before or after hospital admission
- Minimum oxygen saturation (measured within the past day) >=90%
- Vitals (pulse, respiration, temperature, systolic blood pressure) and acute labs (hemoglobin, platelet, white blood cells) measured within the past 2 days
- Albumin, Alanine Aminotransferase (ALT), creatinine measured within the past 30 days
- Weight measurement recorded in the past 2 years
Exclusion Criteria
- Prior intubation, ventilation, high flow oxygen, extracorporeal membrane oxygenation (ECMO), dialysis, or vasopressors during current hospitalization
- Record of prior treatment with CP
- Received long-term care in a domiciliary or nursing home in the past 90 days
- First CP recipient at a site
- Less than 30 days of follow-up
Data sourced from ClinicalTrials.gov (NCT04545047). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.